Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
January 19 2021 - 8:30AM
via NewMediaWire
-- Neovasc Inc. (“Neovasc” or the
“Company”) (Nasdaq, TSX: NVCN) announced today the Neovasc
Reducer™ (“Reducer”) was prominently featured in three peer
reviewed European Journals.
“Management of refractory angina: an update(1)”
was published in the European Heart Journal. This leading
publication came to the conclusion, “At present, accumulating
evidence supports the clinical benefit of the Reducer in
alleviating symptoms of angina in 70–80% of patients with
obstructive CAD of the left coronary system who are not candidates
for revascularization. There may also be a role in treating
patients with microvascular disease.”
The second study published in the American Journal
of Cardiology titled: “Usefulness of Coronary Sinus Reducer
Implantation for the Treatment of Chronic Refractory Angina
Pectoris(2)” stated, “During a median follow-up of 18.4 months, 135
(82.8%) patients demonstrated at least 1 CCS class reduction after
Reducer implantation, and 80 (49%) patients at least 2 CCS class
reduction. Mean CCS class improved from 3.05 ± 0.53 at baseline to
1.63 ± 0.98 at follow-up (p < 0.001). Treatment benefit was also
reflected in a significant improvement in quality of life scores
and in a reduction of the mean number of anti-ischemic drugs
prescribed for patient. In conclusion, in this multicenter,
country-level study, the implantation of CS Reducer in patients
with refractory angina pectoris resulted to be safe and effective
in reducing of angina pectoris and improving quality of life.”
The third peer-reviewed study from the Netherlands
Heart Journal(3) published online 5-year data on the Coronary Sinus
Reducer stated, “In this real-world, multicentre 5-year Dutch
experience, implantation of the CSR was shown to be a safe and
effective treatment for the majority of patients with refractory
angina. Our results support the need for further research
investigating the determinants of effectiveness, ineffectiveness
and long-term follow-up. In conclusion, a CSR is a simple and safe
option for reducing symptoms in patients with RA in the
Netherlands.”
Fred Colen, Neovasc CEO said, “We are more than
pleased that leaders in the European Union Cardiology community
have published data supporting the promise of Reducer. We
cannot thank them enough for their commitment to bringing better
solutions to those suffering from angina. Developing specific
country-level data is a key pillar of our approach to broadening
awareness, adoption and reimbursement in international
markets.”
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is not currently commercially
available in the United States and has been commercially available
in Europe since 2015, and Tiara, for the transcatheter treatment of
mitral valve disease, which is currently under clinical
investigation in select international markets. For more
information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When
used herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, the ability of the
Company to broaden reimbursement in international markets, the
ability of third parties to develop country-level data, the safety
and effectiveness of the Reducer and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, market and other conditions as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Report on Form 20-F and in the Management's
Discussion and Analysis for the three and nine months ended
September 30, 2020 (copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company's forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
(1) European Heart Journal (2020) 00,
1–15
(2) Am J Cardiol 2021;139:22−27
(3) Neth Heart
Jhttps://doi.org/10.1007/s12471-020-01525-8
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Apr 2024 to May 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From May 2023 to May 2024